SAN DIEGO, Oct. 13, 2016 /PRNewswire/ -- Mast
Therapeutics, Inc. (NYSE MKT: MSTX), today announced that the
Company's Chief Executive Officer, Brian M.
Culley, will provide an update related to its business
strategy and clinical development of its product candidates at the
2016 BIO Investor Forum on Wednesday,
October 19, 2016 at 2:30 p.m. Pacific
time in the Elizabethan B Salon at the Westin St. Francis
hotel in San Francisco. The
Company recently announced a strategic focus on its AIR001 (sodium
nitrite solution for intermittent inhalation) program with
continued support for multiple investigator-sponsored Phase 2
clinical studies of AIR001 being conducted at prestigious research
institutions, with interim results from one of these studies
anticipated to be published this quarter.
Interested parties can access a live audio webcast on the Mast
Therapeutics web site at www.masttherapeutics.com. An archived
presentation will be available on the web site for 30 days.
About AIR001
AIR001 is a sodium nitrite solution for
intermittent inhalation via nebulization. Nitrite is a direct
vasodilator and can be recycled in vivo to form nitric oxide
(NO) independent of the classical NO synthase (NOS) pathway.
Nitrite mediated NO formation has several beneficial effects,
including dilation of blood vessels and reduction of inflammation
and undesirable cell growth. Generation of NO from sodium nitrite
is not dependent upon endothelial function and is enhanced in the
setting of tissue hypoxia and acidosis, conditions in which NOS
activity typically is depressed. In early clinical studies, AIR001
demonstrated positive hemodynamic effects with reductions observed
in right atrial pressure and pulmonary capillary wedge pressure, as
well as improvements in mean pulmonary artery pressures, cardiac
output, and exercise tolerance as measured by six-minute walk
distance. In a randomized, double-blind, placebo-controlled Phase
2a study of AIR001 in patients with HFpEF (n=26), the AIR001
treatment group showed a statistically significant decrease in
pulmonary capillary wedge pressure during exercise compared to the
control group and AIR001 was generally well-tolerated.
About Mast Therapeutics
Mast Therapeutics, Inc. is a
publicly traded biopharmaceutical company headquartered in
San Diego, California. The Company
has two clinical-stage investigational new drugs, AIR001 and
vepoloxamer. AIR001, a sodium nitrite solution for
intermittent inhalation via nebulizer, is in Phase 2 clinical
development for the treatment of heart failure with preserved
ejection fraction (HFpEF). More information can be found on
the Company's web site at www.masttherapeutics.com. Mast
Therapeutics™ and the corporate logo are trademarks of Mast
Therapeutics, Inc.
Forward Looking Statements
Mast Therapeutics cautions
you that statements in this press release that are not a
description of historical fact are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified by the use of
words referencing future events or circumstances such as "expect,"
"intend," "plan," "anticipate," "believe," and "will," among
others. Examples of forward-looking statements in this press
release include statements relating to the Company's development
plans for its product candidates and the Company's business plans
and objectives. Forward-looking statements should not be read
as guarantees of future performance or results because they involve
the Company's beliefs and assumptions based on currently available
information and are subject to significant known and unknown risks
and uncertainties that may cause actual performance and results to
differ materially from expectations indicated by the
forward-looking statements. Some of the factors that could cause
actual performance or results to differ include, without
limitation: the Company's need for additional funding to continue
to operate as a going concern; risks associated with the Company's
ability to manage operating expenses and obtain additional capital
as needed; uncertainty related to the Company's ability to remain
in compliance with the terms and conditions under its debt facility
and risk that the Company may be required to repay its remaining
outstanding debt obligation on an accelerated basis and/or at a
time that could be detrimental to the Company's financial
condition, operations and/or business strategy; the impact of
significant reductions in the Company's operations on its ability
to develop its product candidates or maintain compliance with laws
and regulations relating to public companies; the Company's ability
to maintain compliance with NYSE MKT continued listing standards
and policies and to maintain the listing and trading of its common
stock on that exchange; completion of a more detailed analysis of
EPIC data and reporting of additional data from the study;
uncertainties inherent in the conduct of clinical studies and the
risk that the Company's product candidates may not demonstrate
adequate safety, efficacy or tolerability in one or more clinical
studies for approval by regulatory authorities; the potential for
the Company to sell or license part or all of its assets; the
potential for significant delays, reductions, or discontinuation of
current and/or planned development activities if the Company is
unable to raise sufficient additional capital as needed; the
Company's lack of control over the investigator-sponsored clinical
studies of AIR001, including whether any of the studies will
commence or be completed on anticipated timelines, or at all; the
Company's dependence on third parties to assist with important
aspects of development of the Company's product candidates,
including the conduct of its clinical studies, the manufacture and
supply of clinical trial material and drug delivery devices, and
the conduct of regulatory activities, and the risk that such third
parties may fail to perform as expected leading to delays in
product candidate development and additional costs; the risk that
the Company is not able to obtain or maintain effective patent
coverage or other market exclusivity protections for its products,
if approved, or that the use or manufacture of the Company's
products may infringe the proprietary rights of others; and other
risks and uncertainties more fully described in the Company's press
releases and its reports filed with the Securities and Exchange
Commission. The Company's public filings with the Securities and
Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date when made. Mast
Therapeutics does not intend to revise or update any
forward-looking statement set forth in this press release to
reflect events or circumstances arising after the date hereof,
except as may be required by law.
Logo -
http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mast-therapeutics-to-present-at-2016-bio-investor-forum-on-october-19th-300344049.html
SOURCE Mast Therapeutics, Inc.